Free Trial
NYSE:BIO.B

Bio-Rad Laboratories (BIO.B) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$365.08 0.00 (0.00%)
As of 10/5/2026

About Bio-Rad Laboratories Stock (NYSE:BIO.B)

Advanced

Key Stats

Today's Range
$365.08
▼
$365.08
50-Day Range
$309.37
▼
$387.39
52-Week Range
$244.54
▼
$365.08
Volume
10 shs
Average Volume
18 shs
Market Capitalization
$9.76 billion
P/E Ratio
44.25
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bio-Rad Laboratories, Inc. develops, manufactures and sells products and services used in life science research and clinical diagnostics. The company serves academic and government laboratories, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.

Bio-Rad’s Life Science segment provides instruments, reagents, software and consumables for applications including gene expression analysis, polymerase chain reaction, digital PCR, protein research, cell biology, chromatography, electrophoresis and laboratory quality control. Its Clinical Diagnostics segment offers systems and products used in areas such as blood typing and immunohematology, diabetes monitoring, autoimmune testing, infectious disease testing and quality-control management.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia and other international markets. The company operates globally under the leadership of Chairman and Chief Executive Officer Norman D. Schwartz.

AI Generated. May Contain Errors.

Receive BIO.B Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO.B Stock News Headlines

The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.tc pixel
Bio-Rad Laboratories, Inc. Class B
See More Headlines

BIO.B Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $310.70 at the beginning of 2026. Since then, BIO.B shares have increased by 17.5% and is now trading at $365.08.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) posted its quarterly earnings results on Thursday, April, 30th. The company reported $1.89 EPS for the quarter. Bio-Rad Laboratories had a net margin of 8.59% and a trailing twelve-month return on equity of 3.54%.

Bio-Rad Laboratories subsidiaries include Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, QuantaLife, DiaMed Holding AG, Blackhawk Biosystems, and more.

Shares of BIO.B stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/30/2026
Today
10/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO.B
CIK
12208
Employees
7,450
Year Founded
1952

Profitability

EPS (Trailing Twelve Months)
$8.25
Trailing P/E Ratio
44.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$759.90 million
Net Margins
8.59%
Pretax Margin
13.53%
Return on Equity
3.54%
Return on Assets
2.48%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
3.14
Quick Ratio
2.33

Sales & Book Value

Annual Sales
$2.59 billion
Price / Sales
3.77
Cash Flow
$10.02 per share
Price / Cash Flow
36.43
Book Value
$276.16 per share
Price / Book
1.32

Miscellaneous

Outstanding Shares
26,738,000
Free Float
19,150,000
Market Cap
$9.76 billion
Optionable
Not Optionable
Beta
0.93

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NYSE:BIO.B) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners